

INVESTOR PRESENTATION

FEBRUARY 2021



• The context Healthcare



HEALTHCARE: A PIVOTAL MARKET

A segment that can **impact** a country's **economic development**, the keeping of **public accounts** and its very **social cohesion**



AN EVOLVING MARKET

- demographic **ageing** and increased **life expectancy**
- increased **health costs** (chronic)
- **shortage** of healthcare staff (doctors) and resources



2019 ITALY HEALTHCARE EXPENDITURE

115 B €

20% waste and inefficiency

INCREASED
DEMAND
FOR CARE



THE CHALLENGE: to make the **health systems sustainable**, **limiting spending** and improve the **quality of service**



OPPORTUNITIES:
ORGANISATIONAL and
TECHNOLOGICAL RENEWAL
(digital health care)

Rethinking the organisational models and processes used by the health authorities

Your Global Partner for a Better Future

We develop **software, technologies and services** to help **innovating** the models of care, assistance and prevention of the health care systems, **optimizing processes and containing costs**.

A partnership to make **health systems sustainable** and help improve people's health and well-being.



History of Growth

> 30 years of experience, management team with a track record of internal growth and M&As



International footprint

solutions used by more than 2,200 customers in more than 60 countries



Leadership

1st player in Italy: services granting access to care

3rd player in Italy: software solutions for healthcare and social systems



Uniqueness

integrated software, technology and service solutions to optimise the clinical, care, administrative and social processes.



Quality of life


our work helps improve the quality of life

● GPI in figures



A history of steady growth

- **2013 Orizzonte fund** providing equity financing - First minibond issued.
- **2016** merger between GPI and the SPAC CFP1.
Start of trading in the stock market **AIM Italia**.
- **2018** graduated from AIM to MTA **main market** of Borsa Italiana.
- > **€100 M M&A** deals
- **Staff 5,395** (as of 31/12/2019)

Net Profit





HY



Revenue €M



EBITDA €M *


FY



● Strategic Business Areas

TECHNOLOGIES
50.6%

	Pay	2.8
	Automation	4.8
	ICT	4.9
	Software	38.1



SERVICES
49.4%

 Care

Note: % revenues for SBA out of total revenues
referring to FY 2019

● Supply Lines



main SBAs
87.5% of total revenue



Software

- hospital information system
- health social care
- blood transfusion & tissue bank
- health administration
- Business Intelligence, data analytics
- other

Care

- BPO health care administrative svc. (AtC,..)
- telemedicine
- other

Automation

- automated pharmacy warehouse
- automated hospital pharmacy supply chain

other SBAs
12.5 % of total revenue



ICT

- HW & SW on-site / on-line maintenance and assistance
- on-site / on-line system services

Pay

- e-payment and e-mandate solutions
- electronic storage

● Highlights

- **Covid-19**
 - Slowdown in ordinary business, increase in extraordinary business and innovation activities
 - Overall **increase in volume and positive net balance**
- **New solutions and services to tackle the Covid-19**
- **Contract awarded Telemedicine Region Lombardia**
Telemonitoring of Covid-19 patients (40k patients)
- **Additional bond issue of € 20 M** (oversubscribed)
("GPI S.p.A. - 3,50% 2019-2025" total nominal amount 50M€)
- **Contract awarded Region Basilicata**
Sw e AtC svc + Regional Digital Agenda
(€ 14,7 M | duration 2+2 yrs | Gpi 60%)
- **Contract awarded Region Liguria**
Multi-channel mgmt patient intake svc + Help desk for digital health care solutions
(€ 14,9 M | duration 5 yrs | Gpi 60%)
- **Bid-Hit winning ratio 30%**
€ 80 M multiyear value awarded

main M&As

1H2020

- **Oslo Italia** (Business Intelligence Health Care SW, Big Data & Analytics) | € 4.3 M Rev. | 30% EBITDA
- **Umana Medical Technologies**, Malta start up innovative solutions: **nanomaterial tattoo sensors** for remote monitoring

2H2020

- **Assets Haemonetics**, USA (SW Blood Bank)
\$ 11.3 M Rev. | 35% EBITDA | 100 clients in the USA

1H2021

- **Medinfo international Group** (SW Blood Bank)
€ 3.9 M Rev. | 36% EBITDA | 60 clients NHS UK, Army (France, Belgium)



Overview and main results 1H2020

● Resilience and Growth

1H 2020

Revenue **+6.1%**, EBITDA **+8.7%**

Revenue € 117.2 M, +6.1% thanks to the contribution of the SBAs:

- SW € 41.5 M **+2.1%**
- Care € 61.0 M **+5.9%**
- Other € 14.7 M **+20.1%**

1H 2020 marked by

- Covid-19
- 3 acquisitions

EBITDA: € 10.5 M | 9.7% on adj. Revenue

Net Profit: € 0.2 M: Higher D&A for € 1.8 M
(€ 1.1 M amortization of intangibles and
€ 0.7 M depreciation of tangibles)

€M	1H2020	1H2019
Revenue & other income	117.2	110.5
Adjusted Revenue ⁽¹⁾	108.1	99.6
EBITDA	10.5	9.6
EBITDA % of adj. revenue	9.7%	9.7%
EBIT	0.9	1.8
Net profit	0.2	1.3

(1) Net of Temporary grouping of companies (RTI)



FY2019

Gpi

● Financial Highlights

1H2020

A3.1 CERVED Rating confirmed

A- S&P | A3 Moody's | A-1 Fitch

Net working capital

€ 97.4 M (€ 91.3 M FY2019):

- higher inventory for € 1.4 M, higher trade receivables and contract assets and liabilities for € 2.1 M (net of provision for doubtful accounts), reduction in trade payables for € 2.6 M

Shareholders' equity

€ 71.9 M (€ 72.1 M FY2019):

- Fair value of financial assets

Net Debt

€ 90.9 M (€ 82,8 M FY2019)

- reflects the operating flows and the investment strategy of the Group in the 1H2020

Investments: Tot. € 15.8 M | M&A € 9.1 M | R&D € 4.8 M

€M	1H2020	FY2019
Net working capital	97.4	91.3
Non-current assets	134.7	119.4
Other operating assets/(liabilities)	(69.4)	(55.8)
NET INVESTED CAPITAL	162.8	154.9
Shareholders' equity	71.9	72.1
Net financial position	90.9	82.8
TOTAL SOURCES	162.8	154.9




FY2019

Gpi


● Segmentation 1H2020

Revenues 1H2020 by
Strategic Business Area




■ Software ■ Care ■ Other

EBITDA 1H2020 by
Strategic Business Area




■ Software ■ Care ■ Other

Revenues 1H2020 by
Geographic Area



■ Italy ■ International

Software





- Recurring fees**
- 51%
- Contract duration**
- 1-3 years
- Competitive position**
- 3° player ITA



Adj. Revenue €M

Net of Temporary grouping
of companies (RTI)

EBITDA €M



HY
2020




FY
2019

* 2018 EBITDA adjusted by one-time costs for listing on the MTA

Care



Supply Lines
% on total SBA's revenue



Recurring fees

- 97%

Contract duration


- 4-6 anni

Competitive position




- 1° player ITA

Adj. Revenue €M

Net of Temporary grouping
of companies (RTI)



EBITDA €M



* 2018 EBITDA adjusted by one-time costs for listing on the MTA


Other SBAs

HY
2020



Revenue €M



EBITDA €M



FY
2019



Automation

Automated warehouse sales,
maintenance and service fees

- Retail Pharmacies
- Hospital Pharmacies
- Wholesaler and other industries

ICT

Desktop management services fees
other system services


- Healthcare customers
- Non-healthcare PA
- Other private customers

PAY


ePayment services
POS rental and related software

- Large-scale Retail;
- Local PA
- Svc. providers based on POS
- System Integrator


1H 2020 Revenue




1H 2020 EBITDA



● The customers



- GPI worldwide



ITALY

> 40 branches

SOLUTIONS

> 60 countries

Target market
and competitive
environment

● Market Analysis Software

Market value

\$ 70.0 B



|| Source: Gartner (2020 Q2)

Forecast 2020 - World Market Healthcare software+IT services IT

45 %	North America	CAGR 20 – 24: 11.4%
21 %	Western Europe	CAGR 20 – 24 : 9.9%
3.4%	Mature Asia/Pacific	CAGR 20 – 24 : 11.5%
2.3 %	Latin America	CAGR 20 – 24 : 6.3%
5.1 %	Greater China	CAGR 20 – 24: 15.4%

\$ 0.65 B



Forecast 2020 - Italian Market Healthcare software+IT services IT






0.9% of the world market CAGR 20 – 24: **4.9%**

Fairly large National / European economic resources
Recovery Plan: **€ 20 Billion to Health Care**
Telemedicine + Digitization

● Market Analysis






Top Players

Software

Company	Brief description	Focus on HC	Ranking
 Dedalus HEALTHCARE SYSTEMS GROUP	ICT solutions and related services for public and private healthcare providers .	✓	1st
 ENGINEERING	ICT solutions for the segments: finance, industry, telco&utilities and PA .	Through dedicated healthcare division	2nd
 Gpi	ICT solutions, administrative and social-healthcare services for public and private healthcare providers .	✓	3rd
 Reply santer	Software for hospital processes, orders and risk management Group reply part.	✓	4th
 expri via	Digital transformation & ICT services for industries, energy, aerospace, healthcare , PA, etc.	Through dedicated healthcare division	5th

Care

> 28 M citizens reached

Company	Brief description	Ranking
 Gpi	ICT solutions, administrative and social-healthcare services for public and private healthcare providers .	1st
 ALTHEA	Maintenance services for medical devices, operative in 17 different countries.	N/A
 Coopservice	BPO services (e.g. cleaning, security, logistics and healthcare services).	N/A
 Cooperativa ANTHESIS SERVIZI Società Cooperativa per Azioni	Local supplier of services for healthcare and the educational segment, operates in the Region of Veneto.	N/A
 C A P O D A R C O	Local supplier of services for healthcare , operates in the Region of Lazio.	N/A

Strategic intentions 2020-2024

● Strategic guidelines 2020 - 2024



01

EVER MORE
GLOBAL

Strong increase
over the BP
period

Geographical
areas of growth:
DACH, Russia,
China, Middle
East and
America

02

GROWTH IN
PRIVATE
HEALTH
CARE

doubling up of
the segment %
weight

03

ITALY
HEALTH CARE
SW MARKET
LEADERSHIP

Major regional
and national
tenders

M&As

Focus of R&D on
**Machine
Learning** and on
the digital
transformation

04

from
PRODUCTS/
SERVICES to
INTEGRATED
SOLUTIONS

Greater integration of
services | **SW** |
technologies to respond
to the evolution of
healthcare models and
the healthcare demand.


05

from
PROVIDER to
PARTNER

Multi-business
nature with the
contribution of
all SBAs.

M&A Guidelines


● Historic M&A process



● M&A Guidelines



- M&A Guidelines



RESOURCES

- BONDS
- TRADITIONAL FINANCING
- WARRANTS
- SHARES/SHARES
 - Big players
 - Abroad

Investment Attractiveness

Leadership and Uniqueness

Growth and Visibility

Technology and Service

Evolution of market/client

M&A Opportunities

GPI IN THE STOCK MARKET

Bloomberg: GPI:IM

15,909,539 Ordinary Shares (ISIN: IT0005221517)

Price: € 8.20 (5 February 2021)


Capitalisation: € 130.5 M

ANALYST COVERAGE – Target price

Intermonte SIM (14/10/2020): € 10.00 €

Banca Akros (06/11/2020): € 11.00 €

SHAREHOLDING STRUCTURE



● IR Contact details



Via Ragazzi del '99, 13 - 38123 Trento

T +39 0461 381515

investor.relations@gpi.it

Fabrizio Redavid

Mob. +39 335 1035499

fabrizio.redavid@gpi.it

Lorenzo Giollo

Mob. +39 340 8223333

lorenzo.giollo@gpi.it

● Disclaimer

The material in this presentation was prepared by GPI S.p.A. ("GPI" or the "Company") without any form of independent verification; it is general, basic information about the current business of GPI as at the date of this presentation. This information is supplied in summary form and is not complete. This presentation is provided for information only and is not an offer or solicitation of an offer of purchase or sale of securities, nor shall there be any sale or purchase of securities in any jurisdiction in which such an offer, solicitation or sale should be illegal before the registration or qualification in accordance with the laws on securities of that jurisdiction. It is intended exclusively by way of a presentation to investors and is provided for information only. This presentation does not contain all information that may be relevant to an investor.

The information contained in this presentation, including the forecast financial information, must not be considered as advice or recommendations to investors or potential investors in connection with the holding, purchase or sale of securities or other products or financial instruments and does not take into account any specific investment targets nor the financial position. Before acting, it is important to consider the adequacy of information in relation to such subjects and, in particular, independent financial advice should be taken. All securities and product transactions or financial instruments entail risks, which include, amongst others, the risk of adverse or unforeseen market, financial or political developments and, in international transactions, the foreign exchange risk. The information contained in this presentation is confidential and is supplied to the user for information only and cannot be reproduced, re-sent or further distributed to anyone else, nor published, entirely or partly, for any purpose. This presentation is only distributed to and intended for: (A) persons in the European Economic Area Member States (excluding the United Kingdom), who are classed as "qualified investors" under Article 2, paragraph 1, letter e) of Directive 2003/71/EC (as amended and complete with any implementing measures applicable in each Member State); (B) in the United Kingdom, professional investment qualified investors coming under Article 19 (5) of the 2005 Order (financial promotion), the Order of Financial Services and markets and/or companies with high shareholders' equity and other persons to whom it can be lawfully disclosed, pursuant to Article 49,

paragraph 2, letters a) to d) of the Order; and (C) other persons to whom this presentation can be legally distributed and disclosed in accordance with applicable laws (all those pursuant to points (A) to (C) above, indicated as "relevant persons").

The information contained in this presentation may include forecasts. Although the Company believes it has a reasonable basis on which to make the forecasts given in this presentation, GPI warns that forecasts are no guarantee of future performance and that the effective operating results, financial conditions and conditions of liquidity and development of the segment in which GPI operates may differ considerably from those effectively achieved or suggested by the declarations given in this presentation or made by the GPI management team. Past performance is also not a reliable indication of future performance.

GPI makes no promise to update or publicly review the forecasts, even if new information is revealed or for any other reason. The information and opinions given in this presentation or in the declarations made by the GPI management team are given as at the date of this presentation or any other date, if indicated, and are subject to change without notice. Do not rely on the information given in this presentation for any purpose. No express or implicit declaration or guarantee is given by GPI, its subsidiaries or the respective consultants, functionaries, employees and agents, as regards the accuracy of information or opinions or for any loss as may derive directly or indirectly from any use of this presentation or its contents. This presentation is not intended for distribution or use by any person or entity that is a citizen or resident of a place, country or other jurisdiction in which such distribution, publication, availability or use may be in conflict with laws or regulations or which would require any registration or licence within such jurisdiction.